false 0001728328 A1 BC 0001728328 2024-04-16 2024-04-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares














Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 16, 2024





(Exact Name of Company as Specified in Charter)




British Columbia   001-39685   98-1428279
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)


InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.


  V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)


Company’s telephone number, including area code: (604) 669-7207


Not applicable

(Former Name or Former Address, if Changed Since Last Report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class  

Trading Symbol(s)

  Name of each exchange on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company  


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  







Item 7.01 Regulation FD Disclosure.


On April 16, 2024, the Company announced additional preclinical data for INM-089 further demonstrating positive pharmacological effects targeting dry Age-Related Macular Degeneration (“AMD”).


The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits:


The following exhibits shall be deemed to be furnished, and not filed:


Exhibit No.   Description


  News release, dated April 16, 2024  
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 16, 2024 By: /s/ Eric A Adams
    Eric A Adams
    President & CEO





EX-99.1 2 ea020400401ex99-1_inmed.htm NEWS RELEASE, DATED APRIL 16, 2024

Exhibit 99.1




Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com



InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration


Small molecule drug acting as a preferential signaling ligand for CB1/CB2


Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model


Vancouver, BC – April 16, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced additional preclinical data for INM-089 further demonstrating positive pharmacological effects targeting dry Age-Related Macular Degeneration (“AMD”).


Dr. Eric Hsu, SVP of Preclinical Research and Development, stated, “We are very excited with the data from recent preclinical studies demonstrating both significant functional and pathological improvements from INM-089 in the AMD model. While a few treatment options are currently available, their efficacy is limited and may be associated with several undesirable side effects. We see an opportunity for INM-089 to slow the progression and to fill a significant gap in the treatment of this chronic disease.”


Recent Preclinical Data


Data from a recent proof of concept study indicates that INM-089 may be more effective as a therapeutic treatment for dry AMD compared to neovascular, or wet, AMD. More specifically, data suggests INM-089 may be an important candidate for geographic atrophy (“GA”) which is common in more advanced cases of dry AMD, affecting the center of the macula.


In vivo preclinical studies in AMD disease models demonstrated the following significant outcomes for INM-089:


neuroprotection of photoreceptors as well as improved photoreceptors function;


improved integrity of retinal pigment epithelium; and


reduction in extracellular autofluorescent deposits, a hallmark of dry AMD.


Previously, it was demonstrated that INM-089 preserved retinal function and improved the thickness of the outer nuclear layer of the retina, where photoreceptors are located, in an in vivo AMD disease model.




Importance of CB1/CB2 Receptors


INM-089 is proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). CB1 and CB2 receptors are both part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses.


Dry AMD – Unmet Medical Need


AMD is a ‘back of the eye’ disease in which a small area in the central portion of the retina, known as the macula, is damaged. AMD affects the central vision and the ability to see fine details. People with advanced AMD in both eyes cannot recognize faces, read, nor drive. Dry AMD is the most common form, accounting for 85-90% of all AMD cases and is a leading cause of blindness in the developed world. Dry AMD is caused by waste proteins and lipids (oily material) that begin to accumulate due to poor circulation and poor waste-flushing in the eye. The advanced stage of dry AMD is referred to as Geographic Atrophy, with approximately 5 million patients globally suffering from GA. The prevalence of GA is projected to continue to rise in the coming years, with an estimated 18.5 million cases globally by the year 2040.(1)


Next Steps- Advancing Development Activities


InMed has engaged a Contract Development and Manufacturing Organization (“CDMO”) to assist in scale-up manufacturing process development of the active pharmaceutical ingredient (“API”). Furthermore, development work on drug product formulation continues internally to support the next stages of development activities.


Additional preclinical activities are on-going to further understand the mechanism of action including receptor interactions and drug metabolism and pharmacokinetics (“DMPK”) studies.




(1)Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis


About InMed:


InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. We are a clinical-stage company developing a pipeline of proprietary cannabinoid-analog therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.


Investor Contact:


Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1 604 416 0999

E: cclancy@inmedpharma.com





Cautionary Note Regarding Forward-Looking Information:


This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the efficacy of INM-089, INM-089’s ability to treat AMD, marketability and uses for INM-089, the results of further studies into INM-089 and the further development of InMed’s AMD program.


Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.


All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.







EX-101.SCH 3 inm-20240416.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 inm-20240416_def.xml XBRL DEFINITION FILE EX-101.LAB 5 inm-20240416_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 inm-20240416_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.u1
Apr. 16, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 16, 2024
Entity File Number 001-39685
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code 604
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:EntityIncorporationStateCountryCode - ea0204004-8k_inmed.htm 21, 22 ea0204004-8k_inmed.htm inm-20240416.xsd inm-20240416_lab.xml inm-20240416_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0204004-8k_inmed.htm": { "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20240416", "dts": { "inline": { "local": [ "ea0204004-8k_inmed.htm" ] }, "schema": { "local": [ "inm-20240416.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "inm-20240416_lab.xml" ] }, "presentationLink": { "local": [ "inm-20240416_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://inmedpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0204004-8k_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0204004-8k_inmed.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001213900-24-033340-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-033340-xbrl.zip M4$L#!!0 ( /!TD%BDD&/KFQ0 "J3 6 96$P,C T,# T+3AK7VEN M;65D+FAT;>T];5?BR-+?^17]<,_>U;/RDO BH'(/ BJC@@HSX\X73R=II#4D M,0D*\^N?JDZ"!(*B P[L.F=F%-)=75U=[UW=V?_?L*^31V8[W#0._I22Z3\) M,U13X\;MP9^5=K71^/-_Y=A^SX5FT-1P#N(]U[5*J=33TU/R*9,T[=N45"P6 M4T-L$_<:E8:1[>1T6DI=GY^UU1[KTP0W')<:*AMWTKEQ/Q\^/ATW56R=AYKB M-\$@F=0,:'BJ/7>8;)Q/>0]#3=W(ICFOJ1LTY8Z9E:7=E_#P6HP[#.>UE1!G MF"&[/KPZ>V[N1K=_;IIR;6HX7=/N4Q>6$"'E$FDY(>?DK?GX M*IQ"(B,%<&86)SQ3?*Q09TQQC4V1.Q@3'D /.1,TM%EW+MA\"IX�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ea0204004-8k_inmed_htm.xml IDEA: XBRL DOCUMENT 0001728328 2024-04-16 2024-04-16 iso4217:USD shares iso4217:USD shares false 0001728328 A1 BC 8-K 2024-04-16 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street Vancouver CA V6C 1B4 604 669-7207 false false false false Common Shares, no par value INM NASDAQ true false